ICU Share Price Performance
US$4.31
-9.59 (-68.99%)
64.1% undervalued intrinsic discount
US$12.00
Fair Value
Price US$4.31
AnalystHighTarget US$12.00
Fair ValueUS$12.00
Share Pricen/a
SeaStar Medical Holding Corporation Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
ICU Community Narratives
AN
Fair Value US$12 64.1% undervalued intrinsic discount
Adult AKI Trial And High Margins Will Support Strong Long Term Earnings Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Adult AKI Trial And High Margins Will Support Strong Long Term Earnings Potential
Catalysts About SeaStar Medical Holding SeaStar Medical develops and commercializes cell directed extracorporeal therapies, including its SCD platform and QUELIMMUNE, to modulate hyperinflammation in critically ill patients. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$12
64.1% undervalued intrinsic discount
Fair Value
Profit Margin
13.08%
Future PE
31.44x
Price in 2029
US$15.01
Trending Discussion
Recently Updated Narratives
AN
Adult AKI Trial And High Margins Will Support Strong Long Term Earnings Potential
Fair Value: US$12 64.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
SeaStar Medical Holding Corporation Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -3.04
- 95.71%
- -984.60%
- 5.0%
About ICU
- Founded
- 2007
- Employees
- 17
- CEO
- WebsiteView website
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
